# Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention

> **NCT02423915** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 5 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **RADIATION:** Total Body Radiation
- **PROCEDURE:** Fucosylated Regulatory T Cells
- **PROCEDURE:** Cord Blood Infusions
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Sirolimus
- **PROCEDURE:** Bone Marrow Aspiration
- **DRUG:** G-CSF
- **PROCEDURE:** Non-Fucosylated Regulatory T Cells

## Key facts

- **NCT ID:** NCT02423915
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-30
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2021-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423915, "Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02423915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*